Liege, Belgium, 8 August 2022 - 8:30 CET - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to women's health, announces today that it has entered into a senior secured convertible facilities agreement with funds managed by Highbridge Capital Management, LLC (collectively, "Highbridge") and funds managed by Whitebox Advisors LLC (collectively, "Whitebox", and together with Highbridge, each a "Lender"), for a three year term, in an amount of up to EUR 100 million. Part of the proceeds of the loan will be used to repurchase outstanding convertible bonds of the Company held by the Lenders for a principal amount of EUR 34.1 million at a discount.

Read the press release

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 06:33:03 UTC.